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The large T antigen encoded by simian virus 40 (SV40) plays essential roles in the infection of permissive
cells, leading to production of progeny virions, and in the infection of nonpermissive cells, leading to malignant
transformation. Primary mouse embryo fibroblasts (MEFs) are nonpermissive for SV40, and infection by
wild-type SV40 leads to immortalization and transformation of a small percentage of infected cells. We
examined the ability of an extensive set of mutants whose lesions affect SV40 large T antigen to immortalize
MEFs. We found that immortalization activity was retained by all mutants whose lesions are located upstream
of codon 346. This includes a mutant lacking amino acids 168 to 346. We previously showed (M. J. Tevethia,
J. M. Pipas, T. Kierstead, and C. Cole, Virology 162:76-89, 1988) that sequences downstream of amino acid
626 are not required for immortalization of primary MEFs. Studies by Thompson et al. (D. L. Thompson, D.
Kalderon, A. Smith, and M. Tevethia, Virology 178:15-34, 1990) indicate that all sequences upstream of
residue 250, including the domain for binding of tumor suppressor protein Rb, are not required for
transformation of MEFs. Together, these studies demonstrate that the immortalization activity of large T
antigen for MEFs maps to sequences between 347 and 626. Several mutants with lesions between 347 and 626
retained the ability to immortalize at nearly the wild-type frequency, while others, with small insertions at
amino acid 409 or 424 or a deletion of residues 587 to 589, failed to immortalize. The abilities of mutant T
antigens to form a complex with tumor suppressor protein p53 were examined. We found that all mutants able
to immortalize retained the ability to complex with p53, while all mutants which lost the ability to immortalize
were no longer able to bind p53. This suggests that inactivation of the growth-suppressive properties of p53 is
essential for immortalization of MEFs.

Large T antigen encodes a number of activities which
could potentially be involved in the mechanisms of immortalization and transformation. Like some nuclear oncogenes,
large T antigen is a transcriptional activator (6, 27), and the
spectrum of genes whose expression is altered following
infection could play a fundamental role in immortalization
and transformation. T antigen is able to induce host cell
DNA synthesis (8) and activate rRNA synthesis from silent
rRNA genes (65). Most importantly, T antigen physically
associates with a number of cellular proteins. Large T
antigen forms a specific complex with the underphosphorylated species of p105Rb through amino acid (aa) residues 105
to 114 of large T antigen, a sequence homologous to conserved region 2 of the adenovirus ElA proteins (11, 38). A
similar region, also interacting with p105Rb, is found in the
E7 proteins of oncogenic strains of human papillomaviruses
(49). T antigen also binds another cellular protein, 107K/
120K protein, through the same region through which it
binds Rb; the role of either p105Rb or the 107K/120K protein
in growth control is not clear (14, 17). Reintroduction of an
Rb gene into tumor cells which have lost both Rb alleles
restores normal growth properties (20). Mutants with lesions
in the Rb-binding domain of T antigen have reduced transforming ability (25, 71), indicating that binding to p105Rb,
107K/120K, or another related protein may be involved in
the mechanisms by which large T antigen causes transformation.
T antigen also associates with the p53 antioncogene protein and stabilizes it. Loss or inactivation of both alleles of
the p53 gene is found in a substantial fraction of several

Simian virus 40 (SV40) encodes two tumor antigens, large
T antigen and small t antigen. Large T antigen is a multifunctional phosphoprotein. It is localized primarily in the
nucleus and subjected to a number of posttranslational
modifications, including phosphorylation, adenylylation,
glycosylation, and ADP-ribosylation. During lytic infection
by SV40, large T antigen initially activates and subsequently
represses transcription from its own promoter and activates
the late promoter (6, 28, 55, 79). It also has the potential to
activate a number of cellular and other viral promoters, but
the biological importance of these activations remains unclear (1, 56).
T antigen plays an essential role in initiation of viral DNA
replication, and its helicase activity appears to be involved in
elongation during viral DNA replication (for reviews, see
references 5 and 54). In addition, large T antigen immortalizes primary cells and transforms established rodent cell
lines (for a review, see reference 58). Large T antigen is
sufficient to cause full transformation of primary rodent cells
in most cases. Small t antigen may help large T antigen to
transform cells in certain circumstances (4).
Large T antigen possesses both specific and nonspecific
DNA-binding activities, ATPase activity, and ATP-dependent helicase activity. These biochemical activities are directly involved in viral DNA replication (5), but none
cosegregates with the immortalizing or transforming capability of T antigen (10, 43, 44, 71).
*
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different human tumors (2, 22, 23, 39, 50, 69, 75). Introduction of wild-type copies of p53 into transformed cells suppresses their growth (3, 12, 45-47); the wild-type gene is also
able to reduce the frequency of transformation of cultured
cells by several oncogenes (16, 18). In contrast, some mutant
forms of p53 are able to immortalize cells in culture and
cooperate with the ras oncogene to transform primary rat
embryo fibroblasts (REFs) (24). The presence of some
mutated alleles in a heterozygous state with a wild-type copy
of p53 may confer a growth advantage on these cells (32).
Thus, wild-type p53 appears to be a tumor suppressor gene
while some mutant alleles behave as dominantly acting
oncogenes.
The regions of T antigen essential for this interaction have
not been well mapped. A few mutants unable to bind p53
have been described (35, 52). These mutants have small
deletions in the vicinity of aa 580 to 590 of large T which
render the mutant proteins unstable and may also bring
about major changes in their conformation. Manfredi and
Prives (41) showed that hybrid SV40-polyomavirus T antigens containing residues 337 to 708 of SV40 large T bound
p53 while a hybrid containing residues 411 to 708 did not. p53
also forms complexes with other viral proteins which play
roles in transformation. The adenovirus E1B 55-kDa polypeptide interacts with p53, as does the E6 protein of oncogenic strains of human papillomaviruses (59, 61, 76). Association of p53 with these tumor virus proteins could play a
role in their transforming or immortalizing activities or both.
T antigen also associates with DNA polymerase a
(through aa residues 1 to 83) (13) and a 73-kDa hsp-like
protein (through aa residues 1 to 178) (60). These proteins
are also possible cellular targets through which T antigen
interactions could lead to immortalization or transformation.
The transforming proteins of DNA tumor viruses have
long been model systems for studying oncogenesis. Adenovirus ElA proteins resemble SV40 large T antigen in that
both are transcriptional regulatory proteins and are able to
alter cellular growth control. ElA proteins can immortalize
primary cells and cooperate with adenovirus E1B proteins
and other oncogene proteins, such as activated ras gene
products, to bring about full transformation of primary rat
cells (57). ElA proteins can also activate and repress viral
and cellular gene expression (19, 33, 34, 36, 63). Two regions
of ElA, aa residues 30 to 60 and 121 to 127, respectively,
were found to be responsible for the immortalization and ras
cooperation functions. These regions are conserved among
different adenovirus serotypes (78) and have homology to
portions of SV40 large T antigen and human papillomavirus
E7 protein (15). This region of homology has been shown to
be essential for binding to p105Rb (11, 15, 49, 77).
Immortality of cells is a recessive phenotype, and immortal human cell lines have been assigned to at least four
complementation groups (53). All SV40-immortalized cell
lines except one belong to one complementation group,
suggesting that SV40 disrupts one of several distinct cellular
functions whose alteration can lead to immortalization of
primary cells. Assays for the immortalization function of T
antigen generally have used primary mouse or rat cells.
Primary C57/BL6 mouse embryo fibroblast (MEF) cells can
be immortalized by transfection of the gene encoding large T
antigen (70), and the amino-terminal 626 aa of T are sufficient
for immortalization (71). Deletion mutants which encode T
antigens missing aa 1 to 127 or 121 to 250 were also able to
immortalize primary MEF cells (73). Therefore, specific and
nonspecific DNA-binding activities; DNA helicase activity;
binding to p1o5Rb, 107K/120K, and hsp73; and the adenovi-
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rus helper-host range function are not essential for immortalization of primary MEF cells. In contrast, the aminoterminal 135 aa of large T appear to be sufficient for
immortalization of primary REFs (31, 51, 64).
To explore the mechanisms of immortalization by SV40
large T antigen further, a large set of point, linker insertion,
and deletion mutants were assayed for immortalization by
using primary C57/BL6 MEFs. In agreement with earlier
studies, we found that the N-terminal portion of large T,
including the p105Rb-binding site, was dispensable for immortalization of primary mouse cells. Analysis of immortalization by mutants with large deletions allowed us to narrow
the domain important for immortalization further to residues
347 to 626. We examined several mutants with small insertions or deletions within the 347 to 626 region and found
perfect cosegregation between the abilities of these mutant
large T antigens to immortalize primary mouse cells and
their abilities to bind p53.
MATERIALS AND METHODS
Plasmids, cells, and tissue culture. REF52 cells are an
established REF cell line (37) and were a gift from Jim Pipas
(University of Pittsburgh, Pittsburgh, Pa.). They were grown
in Dulbecco's modified Eagle's medium (DMEM) supplemented with antibiotics and 10% fetal bovine serum (FCS).
This medium was supplemented with 500 ,ug of G418 per ml
when appropriate for drug selection following transfection
with pSV2neo. pSV2neo contains a bacterial neomycin
phosphotransferase gene (66). Wild-type and all mutant
SV40 DNAs were cloned into the EcoRI site of pUC18 in an
orientation in which the two BamHI sites were located close
together. Standard techniques were used for bacterial
growth and transfection (40), and large-scale plasmid purification was done by CsCl-ethidium bromide buoyant density
centrifugation (42).
Mutants and mutant preparation. Many of the mutants
used in these studies have been described previously. Mutants in the 2400 series that carry deletions at various DdeI
sites within the early region of SV40 were described previously (74) and produce nearly full-size T antigens lacking 1 to
4 amino acids. Mutants with a 12-bp linker (5'-TCGCGATC
GCGA-3') inserted at various sites within the SV40 early
region belong to the 2800 series and have also been described
previously (83). This linker contains two sites for NruI and
one for PvuI. Also included in the 2800 series are some
deletion mutants. Mutant dlA2834 has a deletion of codon 85
(84). Mutants dlA2837, dlA2838, and dlA2839 were prepared
from linker insertion mutants by digesting appropriate mutants with NruI, which cuts within the linker, and XbaI,
which cuts each plasmid once within the polylinker region.
By combining appropriate fragments from two linker insertion mutants, sequences between the sites of the linkers
were deleted. Mutant dIA2837 was prepared by using mutants inA2815 and inA2819; it lacks sequences encoding aa
168 to 346 and contains the 12-bp linker at the site of the
deletion. Mutants dlA2838 and dlA2839 were prepared by
using mutants inA2809 and inA2827 and lack sequences
encoding aa 409 to 520. Mutant dlA2838 contains the 12-bp
linker at the site of the deletion, while mutant dlA2839
contains only half of the linker (a single NruI site).
Mutant designations. Within the text, mutants are designated by their numbers. For insertion mutants, the amino
acid codon at the site of the insertion is given in parentheses
following the mutant number. For deletion mutants, the
amino acids missing from the T antigen encoded by the
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mutant genome are listed in parentheses. Two point mutants
prepared in other laboratories [Kl (Q107K) (25) and SVcT
(K128Q) (30)] and one deletion mutant [Met-128 (Aaa 1-127)
(73)] were also included in these studies. For point mutants,
the amino acid change created by the mutation is given in
parentheses following the mutant number.
Preparation of primary MEF cells. Primary MEF cells
were prepared from 11 to 14-day-old C57/BL6 mouse embryos as previously described (70). The heads and limbs
were removed, and the torsos were cut into 1- to 2-mm
chunks and minced. The tissue was then trypsinized to
produce a single-cell suspension. The cells were cultured
in DMEM containing 10% FCS, 7.5% NaHCO3, 25 mM
HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid) (pH 7.3), and 3% glutamine or frozen in liquid nitrogen
for subsequent use. Immortalization assays were performed
on cells prior to their fourth 1:3 subculturing. The primary
MEFs used in some experiments were a gift from M. J.
Tevethia (Hershey, Pa.).
Immortalization assays. MEF cells (1.5 x 105) were seeded
into 100-mm-diameter plates on the day before transfection.
Cells were cotransfected with 5 ,ug of SV40 wild-type or
mutant plasmid DNA, 1 pug of pSV2neo, and 10 ,ug of
high-molecular-weight salmon sperm DNA as the carrier.
The standard calcium phosphate transfection procedure described elsewhere (83) was used. The cells were exposed to
the calcium phosphate precipitate for 6 to 8 h. The medium
was removed, and the cells were washed twice with Trisbuffered saline (TS; 25 mM Tris-Cl [pH 7.5], 137 mM NaCl,
5 mM KCI, 0.6 mM Na2HPO4, 0.05 mM MgCl2, 0.7 mM
CaCl2) and fed with fresh medium containing 10% FCS. The
medium was changed every 3 to 4 days, and 400 ,ug of G418
per ml was added to the medium 6 days after transfection.
The cells were stained with 0.5% methylene blue 2 to 3
weeks after transfection, and the number of colonies was
scored.
Immunoprecipitations and analyses of p53 binding. The
stabilities of the T antigens encoded by dlA2837, dlA2838,
and dlA2839 were analyzed in pools of REF52 cells expressing mutant T antigens. The abilities of wild-type and mutant
T antigens to bind p53 were examined in BALB/c 3T3 cell
lines or pools expressing mutant T antigens, except that
C57/BL6 MEF cell lines expressing mutant T antigens were
used for mutants in the 2400 series. The abilities of the T
antigens encoded by mutants dlA2837 and dlA2838 to complex with p53 were analyzed in transiently transfected
BALB/c 3T3 cells. Cells (2 x 105) were seeded onto 60-mmdiameter plates on the day before labelling. These exponentially growing cultures were washed twice with TS and
incubated for 1 to 1.5 h at 37°C in 2 ml of DMEM lacking
methionine and containing 2% dialyzed FCS. The medium
was removed, and the cells were labelled for 2 to 3 h with 100
,uCi of [35S]methionine (Dupont, Boston, Mass.) in 0.7 ml of
DMEM lacking methionine and containing 2% dialyzed
FCS. Cultures were harvested by washing twice with TS,
followed by lysis of cells with 0.5 ml of EBC buffer (50 mM
Tris-Cl [pH 8.0], 100 mM NaCl, 0.5% Nonidet P-40, 0.1 U of
aprotinin per ml, 1 nM phenylmethylsulfonyl fluoride, 10 ,ug
of leupeptin per ml [11]) for 20 m at 4°C. The cellular debris
were removed by centrifugation for 15 min at 4°C in a
microcentrifuge. REF52 cell extracts were precleared by
addition of 20 ,ul of Sepharose A beads for 30 min at 4°C.
Extracts from identical numbers of cells were mixed with 5
to 10 ,ul of a mixture of mouse ascites fluids containing
monoclonal antibodies pAB901 and pAB902 (a gift from S.
and M. J. Tevethia) or tissue culture supernatant containing
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monoclonal antibody pAB421. pAB901 and pAB902 antibodies recognize denaturation-resistant determinants located at
the carboxy and amino termini of large T antigen, respectively (72). pAB421 antibody recognizes p53. Mixtures were
rocked for 1 h at 4°C. A 20-[LI volume of protein A-Sepharose
beads (1:1 mixture in TS-bovine serum albumin [11]) (Sigma)
was added to the mixture, and rocking was continued for 30
min at 4°C. The Sepharose beads were pelleted by centrifugation and washed three times with 1 ml of EBC buffer at
4°C. Immunoprecipitated proteins were released by heating
in sample buffer for 15 min at 70°C and analyzed by electrophoresis in sodium dodecyl sulfate (SDS)-7.5% or 10%
polyacrylamide gels, followed by fluorography. When stabilities of mutant proteins were being examined, cultures were
labelled as described above for 3 h, washed twice with TS,
and incubated in DMEM containing 10% FCS. Cultures
were harvested after chase periods of 0, 5, and 17 h and
processed as described above.
RESULTS

The experiments reported here were conducted to determine more precisely which regions of SV40 large T antigen
are required for immortalization of primary MEFs and to
search for correlations between this activity of T and its
other properties. We used primary MEFs to study immortalization because the assay is quantitative and because cells
which do not become immortal through expression of wildtype or mutant T antigen undergo senescence during the
course of the experiment (70).
New mutants prepared for these studies. While most of the
mutants used in these studies have been described in previous work from this laboratory or others, three mutants not
previously described were also used. Each of these new
mutants was prepared from a pair of linker insertion mutants
by combining appropriate DNA fragments to generate new
mutants deleted for the information between the sites of the
inserted linker in each parent. By using pairs of mutants with
the linker in the same reading frame, these new mutants
were expected to encode large T antigen shortened by the
removal of internal amino acids encoded between the sites at
which the linkers were inserted in the parental viral genomes. Two of the mutants have the same deletion and
produce T antigens lacking aa 409 to 520. One of these two
mutants (dlA2839) has an insertion of two aa and the other
(dlA2838) has an insertion of four aa at the site of the
deletion.
Pools of REF52 cells resistant to G418 and expressing
each mutant T antigen were obtained as described in Materials and Methods. To confirm that the T antigens encoded
by the new mutants were of the expected sizes and to
examine their stabilities, cell pools were radiolabelled with
[35S]methionine for 3 h and chased in medium containing
cold methionine for 0, 5, or 17 h. Extracts of these cells were
immunoprecipitated with monoclonal antibodies recognizing
the N and C termini of large T. The autoradiogram resulting
from this experiment is shown in Fig. 1. These T antigens
were readily detected and were of the expected sizes. The T
antigen produced by dlA2837 was as stable as wild-type T
antigen (compare lanes 1 to 3 with lanes 10 to 12), and those
produced by dlA2838 and dlA2839 were quite unstable, with
half-lives of less than 1 h (lanes 4 to 6 and 7 to 9). Mutant
inA2807(aa 302) was previously shown to encode a very
unstable T antigen (83) and is included here for comparison.
Immortalization of primary C57/BL6 MEF cells. Primary
MEF cells were seeded on 100-mm-diameter plates at a low
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FIG. 1. Stabilities of mutant SV40 large T antigens (Tag). Immunoprecipitates of labelled cell extracts were electrophoresed on

SDS-10o polyacrylamide gels and autoradiographed. The molecular
sizes in kilodaltons are indicated at the left. The positions of the T
antigens are indicated by the arrowheads to the right. Hours of chase
time are indicated above the lanes. WT, wild type.

density so that the cells would become senescent before a
monolayer of cells was formed. Only immortalized cells
form colonies under these conditions. In each experiment,
duplicate plates were transfected with each viral DNA. A set
of linker insertion mutant and a smaller number of deletion
and point mutants were examined in this study. Most mutants were examined in two independent experiments. The
results are presented in Table 1 and summarized in Fig. 2.
All mutants with lesions in the first exon [in2801(aa 5),
inA2803(aa 35), and dlA2831(aa 5 to 35)] were able to immortalize primary MEF cells, as was mutant Met-128(Aaa 1 to
127), which lacks the first 127 aa of large T antigen. These
results are consistent with those of Thompson et al., who
showed that the first 250 aa of large T antigen were not required for immortalization (73). Furthermore, mutant dIA2837
(aa 168 to 346) was also able to immortalize primary MEF
cells. These results set the proximal boundary of the minimum sequences needed to immortalize primary MEFs at residue 347 and indicate that the zinc finger motif of large T antigen is not required for immortalization. Previously, we showed
(71) that a mutant missing aa residues 627 to 708 immortalized
well as the wild type. Thus, only the sequences between

as

347 and 626

are

required for immortalization.

Mutants inA2809(aa 409) and inA2811(aa 424) were unable
to immortalize MEF cells. These two mutants encode stable
mutant T antigens and retain the host range function. In
addition, inA2809 retains the abilities to bind specifically to
viral DNA (84) and form oligomers (81). These results
suggest that the mutations are in a specific region essential
for immortalization of MEFs. Furthermore, deletion mutants dlA2838(aa 409 to 520) and dlA2839(aa 409 to 520) also

failed to immortalize. The only other mutant completely
defective for immortalization in these assays was dlA2433(aa
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587 to 589), which we previously reported to be defective for
immotalization (71). The inability of a mutant T antigen to
immortalize could be due to instability, and several of the T
antigens defective for immortalization encode T antigens
with reduced stability. We note, however, that mutant
inA2807(aa 302) was able to immortalize, although only
about one-quarter to one-half as well as wild-type T. The T
antigen of this mutant was no more stable than those of
immortalization-defective mutants such as dlA2838(aa 409 to
520) and dlA2839(aa 409 to 520) (cf. Table 1, Fig. 1, and
reference 83). All of the other linker insertion mutants tested
were able to immortalize primary MEFs. Two mutants
affecting the Rb-binding site [Kl (Q107K) and dl2441(aa
106)] immortalized well. All four mutants affecting small t
antigen and-one which affects only small t antigen (inA2829)
also immortalized MEF cells, indicating that small t was
dispensable for this function.
p53 binding by mutant T antigens. Formation of complexes
between T antigens and mouse p53 was examined in extracts
of mouse cell pools, cloned mouse cell lines, or cloned rat
cell lines expressing wild-type or mutant T antigens. The
ability of p53 to associate with various T antigens was
analyzed by immunoprecipitation. Exponentially growing
cells were labelled with [35S]methionine. Labelled-cell extracts were immunoprecipitated with anti-T or anti-p53
monoclonal antibodies and analyzed on SDS-polyacrylamide
gels. The results are summarized in Fig. 2; representative
autoradiographs of the gels are shown in Fig. 3.
In Fig. 3a, coimmunoprecipitation of p53 and large T
antigen by anti-T antigen (pAb902) or anti-p53 (pAb421)
antibodies was examined for the two insertion mutants
inA2809(aa 409) and inA2811(aa 424) and compared with that
for wild-type T antigen and unstable mutant inA2807(aa 302).
Although the amounts of p53 precipitated by an anti-p53
antibody were within two- to fourfold of each other (lanes 2
to 5), only wild-type and inA2807(aa 302) T antigens were
coprecipitated (lanes 2 and 5). Examination of the immune
complexes retrieved from the anti-T antigen precipitate
revealed the presence of p53 from the extracts of inA2807and wild-type-expressing cells (lanes 7 and 10) but no
increase over the neomycin-resistant control from either
inA2809- or inA2811-expressing cells (lanes 6, 8, and 9).
Figure 3b shows immunoprecipitates from extracts of
transfected cells expressing mutant T antigens dlA2837(aa
168 to 346) and dlA2838(aa 409 to 520) compared with those
expressing the wild type and inA2807(aa 302). Note the
different mobilities of the deletion mutant T antigens indicated by the arrowheads at the right of the panel. Anti-p53
antibodies coprecipitated T antigen from cells producing
dlA2837(aa 168 to 346), inA2807(aa 302), and wild-type T
antigens (lanes 1, 3, and 4) but not from cells producing
dlA2838(aa 409 to 520) T antigen (lane 2). When portions of
the same extracts were immunoprecipitated with pAb901
plus pAb9O2 (anti-T antigen), p53 coprecipitated with all but
dlA2838(aa 409 to 520) (compare lanes 6, 8, and 9 with lane
7). Although the data shown in Fig. 3b represent immunochemical analyses of REF52 cells expressing various T
antigens, the same results were obtained with transfected
murine BALB/c 3T3 cells (data not shown).
Thus, the T antigens of five mutants with lesions in the 347
to 626 region, inA2809(aa 409), inA2811(aa 424), dlA2838(aa
409 to 520), dlA2839(aa 409 to 520), and dlA2433(aa 587 to
589), all failed to bind to p53. dlA2433(aa 587 to 589),
dlA2838(aa 409 to 520), and dlA2839(aa 409 to 520) encode
unstable large T antigens, while inA2809(aa 409) and
inA2811(aa 424) T antigens are stable (83). These were the
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TABLE 1. Immortalization of primary MEF cells by SV40 large T antigen mutants
DNA
Amino
acid
No. of immortal colonies/platea

Amino acid

DNA

lesion

None (mock infection)
pSV2neo
Wild type
2801
2831
2803
Met-128
2441
K1
SVcT
2815
2817
2837
2807
2819
2809
2838
2839
2811
2821
2823
2827
2828
2433
2829

Expt 1

0,
2,
39,
42,
14,
19,

in5
dI5-35 + in
in35
dll-127
d1106
Q107K
K128Q
in168
in219
d1168-346 + in
in303
in346
in409
dl409-520 + in
d1409-520 + in

0 (0.00)
0 (0.03)
31 (1.00)
50 (1.31)
12 (0.37)
21 (0.57)

4, 5 (0.13)
8, 8 (0.23)
29, 60 (1.27)

0,
9,
21,
26,
26,

in520
in520
dl587-589
in173 (small t)

Expt 3

0, 0 (0.00)
3, 4 (0.07)
56, 44 (1.00)

0, 0 (0.00)
1, 1 (0.04)
27, 21 (1.00)

22, 28 (0.50)
23, 16 (0.39)
14, 16 (0.30)
41, 43 (0.84)
48, 41 (0.89)
15, 30 (0.45)
12, 14 (0.28)

8, 12 (0.42)
14, 13 (0.56)

26,
16,
18,
2,
4,
2,
2,

9, 7 (0.23)
10, 12 (0.31)
0, 1 (0.01)

in424
in460
in464

Expt 2

1 (0.01)
22 (0.44)
20 (0.59)
34 (0.86)
28 (0.77)

13, 28 (0.85)

8, 12 (0.42)

22 (0.48)
11 (0.27)
36 (0.54)
4 (0.06)
2 (0.06)
0 (0.02)
6 (0.08)

0, 1 (0.02)
1, 0 (0.02)
1, 0 (0.02)
4, 0 (0.08)
11, 13 (0.50)

1, 3 (0.04)
40, 47 (1.24)

a
The first two numbers are the numbers of colonies from two parallel plates in each experiment. The number in parentheses is the level relative to that of
wild-type SV40 DNA in each experiment.

only mutants with deletions or insertions that failed to
immortalize primary MEF cells. Four other mutants with
lesions in this region, inA2821(aa 460), inA2823(aa 464),
inA2827(aa 520), and inA2828(aa 520), were able to bind p53
(data not shown) and immortalize primary MEFs. We reported previously (71) that mutants dlA2432(aa 507 to 509)

00
00

and dlA2462(aa 509) were able to bind p53 and immortalize
primary MEFs as well as wild-type large T. Thus, all
mutants able to bind p53 immortalized primary MEFs, while
none of the mutants defective for p53 binding were able to
immortalize these cells.
All the mutant large T antigens examined with lesions
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within the first 400 aa residues bound to p53. These include
dlA2837(aa 168 to 346), indicating that T antigen sequences
upstream of residue 346 are not required for binding of p53
(Fig. 3b, cf. lanes 1 and 6). This finding, coupled with the
earlier finding that mutant dlA2465(aa 627 to 708) bound p53
(71), indicates that the p53-binding domain is contained
within residues 347 to 626 of large T.
DISCUSSION

Tumorigenesis is a multistep process. Tumors may result
from alteration of multiple proto-oncogenes, loss of multiple
tumor suppressor genes, or a combination of proto-oncogene
mutations and tumor suppressor gene loss. Many studies
have shown that the combined action of multiple altered
proto-oncogenes is sufficient to convert primary cells into
immortalized, fully transformed cells (29, 57; for a review,
see reference 21). SV40 large T antigen is a multifunctional
protein and, acting alone, is able to cause immortalization
and transformation of primary rodent cells. The recent
finding that T antigen associates with at least two tumor
suppressor proteins, p105Rb and p53, has shed light on the
mechanisms whereby a single protein can drive primary cells
all the way to full transformation.
In the studies described here, primary MEF cells were
used to measure the immortalization activities of mutant
large T antigens. Immortalization of primary cells is a critical
step along the path to full transformation.
Immortalization of primary MEFs by large T antigen.
Immortalization of primary MEF cells has now been localized to the carboxy-terminal half of the T antigen. Deletion
mutants missing the first 127 aa residues or residues 125 to
250 were able to immortalize primary MEF cells at the
wild-type frequency (73). The results shown here (Table 1),

together with our previous results obtained with the 2400
series of deletion mutants (71), further narrow down the
minimum sequences sufficient for immortalization of primary MEFs to sequences between aa residues 347 and 626 of
large T antigen. p105Rb and plO7/pl20 binding cannot be
essential for the immortalization function of SV40 large T
antigen, since mutants missing the p105Rb-binding site were
still capable of immortalizing MEF cells [reference 73 and
Met-128(Aaa 1 to 127) in Table 1].
Mutants dlA2838(aa 409 to 420), dlA2839(aa 409 to 520),
and dlA2433(aa 587 to 589) were unable to immortalize
primary MEF cells, suggesting that the region between aa
400 and 600 encodes an activity essential for immortalization
and transformation of large T antigen. However, the instability of the large T antigens encoded by these mutants
makes it difficult to draw firm conclusions based on these
mutants. However, mutants inA2809(aa 409) and inA2811(aa
424) also failed to immortalize primary MEF cells, and these
mutants encode stable T antigens (83). These mutant T
antigens failed to bind p53, suggesting that p53 binding plays
an essential role in the immortalization of primary MEFs. In
contrast, mutants inA2821(aa 460), inA2823(aa 464),
inA2827(aa 520), and dIA2432(aa 507 to 509) (71) retain the
abilities to immortalize primary MEFs and bind p53. Thus, T
antigen between residues 347 and 626 contains some portions where mutations do not affect p53 binding or immortalization and other portions where mutations knock out
both p53 binding and immortalization. It remains to be tested
whether the p53 binding is sufficient for a mutant large T
antigen to immortalize primary MEF cells.
The mutation of dlA2433(aa 587 to 589) may not be within
the p53-binding site, because a 46-kDa proteolytic fragment
spanning residues 131 to 517 was able to bind p53 (62).
However, those studies used proteolysis under conditions in
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which both free T antigen and T bound to various proteins,
including p53, were substrates for proteolysis. Therefore,
they reveal the nature of fragments bound to p53 following
proteolysis. It is possible that formation of a complex
between T antigen and p53 requires a region of T antigen
extending further towards the C terminus than residue 517.
For example, sequences including the hydrophobic region
(570 to 590) may be required to maintain a conformation able
to bind p53 but may not be required to hold p53 in the
complex once it has formed. In fact, dlA2433 T antigen is
very unstable, does not form oligomers larger than dimers
(81), and lacks many conformationally sensitive epitopes
located in the carboxy-terminal half of the polypeptide (9). A
point mutant at the same region, 5080(P584L), has similar
properties (68). These results suggest that the hydrophobic
region between aa residues 570 and 590 plays an important
structural role in maintaining the correct conformation of the
protein and that mutations in this region may cause an
altered overall conformation for the carboxy-terminal half of
the protein, resulting in instability. Although the aa 131 to
517 fragment was the smallest one found complexed with
p53, the studies presented here with mutant dlA2837(aa 168
to 346) demonstrate that the sequences between 168 and 346
are not required for p53 binding. Thus, the upstream boundary for p53 binding must lie between residues 346 and 409
(the most proximal site at which an inserted linker led to loss
of immortalization activity and p53 binding). Similarly, the
distal boundary for these functions must lie between residues 587 and 626.
We have examined the abilities of several of these mutants
to bind rat and monkey p53; in all cases, mutants which were
able to bind mouse p53 also bound p53 from the other
species examined. Similarly, mutants defective for binding
to mouse p53 were defective for binding to p53 of other
species (82).
How is immortalization related to other properties of large
T antigen? One of the overall goals of our investigations is to
gain an insight into how the various activities of large T
antigen are related to one another. Figure 2 shows a schematic illustration of the portions of T antigen required for its
various activities. Amino acid residues responsible for transformation of 1OT1/2 cells are located within the first 121 aa
residues of large T antigen (67), where some are shared with
small t antigen. Clearly, the sequences required for transformation of 1OT1/2 cells are completely nonoverlapping with
those required for immortalization of primary MEFs. This
part of the large T antigen is involved in DNA polymerase a
binding (13), transcriptional activation of viral and cellular
genes (84), and binding to pl05Rb and plO7/pl20 (14, 17).
The finding that mutants able to immortalize as well as
wild-type T antigen include some [dlA2411(aa 143 to 146)
and inA2815(aa 168)] that were completely defective for
transactivation of the SV40 late and Rous sarcoma virus long
terminal repeat promoters (84) is interesting and raises the
possibility that the activities of large T antigen responsible
for transactivation of the SV40 late and Rous sarcoma virus
long terminal repeat promoters are not involved in immortalization. This is reminiscent of results obtained in studies
on the adenovirus ElA protein, in which the transcriptional
activation activity of ElA maps to the unique portion of the
289-aa 13S mRNA product of the ElA gene, a region known
to be completely dispensable for ElA immortalization (48).
Nevertheless, it remains possible that transactivation of
some cellular genes is important for immortalization and that
mutants which failed to immortalize primary mouse cells
might not be able to transactivate these genes. It is also
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possible that mutants defective for transactivation of the
SV40 late and Rous sarcoma virus long terminal repeat
promoters in monkey kidney cells might be able to activate
transcription from these promoters in other types of cells or
in cells from other species.
The immortalization assays described in this report were
conducted with primary mouse cells. Studies on immortalization by adenovirus ElA have used primary rat cell
cultures (either REFs or baby rat kidney cells). Those
studies indicate that binding of p1O5Rb (or a related protein)
by ElA is required for immortalization, and this result
contrasts with our finding that the p105Rb-binding region of
large T was not required for mouse cell immortalization.
Some investigators have studied immortalization of rat cells
by mutants of SV40 and polyomavirus. The studies with
polyomavirus indicate that binding of p105Rb to polyomavirus large T antigen is important for immortalization of rat
cells (31); studies with SV40 (64) demonstrated that rat cells
could be immortalized by a mutant encoding an N-terminal
fragment of large T antigen which would have retained the
ability to bind p1O5Rb but could not have bound p53.
Chen and Paucha (7) reported that the ability of SV40 large
T antigen to bind p1O5Rb was not required for immortalization of either MEFs or rat REFs. Their findings obtained
with MEFs agree with the results presented here and with
those obtained by Thompson et al. (73). Chen and Paucha's
finding that immortalization of rat cells did not require
p1O5Rb binding is in contrast to the findings of other investigators who have examined rat cell immortalization by
polyomavirus and human adenoviruses. However, the protocol they used for immortalization involved subculturing of
colonies which arose on plates of cells transfected by wildtype or mutant DNAs. They estimated that expansion of
colonies in this manner represented approximately 17 cell
doublings. While primary MEFs undergo senescence within
17 doublings, this may not be true for REFs. Consequently,
it is uncertain that colonies of REFs expressing mutant T
antigens were truly immortal. We are extending our studies
to primary rat cells to understand and, we hope, resolve the
disagreements among studies conducted previously by others. These studies are required to determine whether these
earlier results reflect fundamentally different requirements
for and mechanisms of immortalization of REFs and MEFs
by SV40 and other DNA tumor viruses.
While only a small portion of large T is required to
transform mouse 1OT1/2 cells, Srinivasan et al. (67) showed
that much more of the protein is required for transformation
of REF52 cells and similar results have been obtained with
other established rodent cell lines. The set of mutants used in
those studies did not permit mapping with precision the
sequences required and those dispensable for transformation. We are currently examining the abilities of the mutants
used in the studies described here to transform 1OT1/2 and
REF52 cells. It is clear, however, that the immortalization
function of large T requires some of the sequences required
for REF52 transformation. Whether REF52 transformation
also requires p53 binding is not known.
In this light, it is worth noting that ElA and E1B can
cooperate to bring about full transformation of primary
REFs and primary baby rat kidney cells. While E1B is also
a p53-binding protein, it binds sequences of p53 different
from those bound by SV40 large T and the ability to form a
complex with p53 is not essential to the transformation
activity of ElB (26, 80). The studies currently under way
should provide insight into whether p53 binding plays a role
in transformation by SV40 large T antigen.
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